• RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
    May 01, 2023

    Vivos April 2023 Update | IsoPet® - RadioGel™

    • VX-2 Animal Study Phase Two Testing Completed | New IsoPet® Clinic being licensed

    We are pleased to share progress updates on the following projects.

    ADVISORY BOARDS

    We just reconstituted and strengthened our advisory boards. They provide us with valuable senior guidance.

     

    Veterinary Medicine Advisory Board

     

    • Alice Villalobos, DVM our previous chairperson is retiring after many years of valuable consultation. She left us a legacy by referencing IsoPet® several times in her textbook “Canine and Feline Geriatric Oncology.”

    • Richard Weller, DVM, DACVIM (internal medicine, oncology) is the new Board Chairperson. 

    • John E. Hendrich, PhD, DVM, retired co-owner of the Ventana Animal Hospital and Riverside Animal Hospitals in NM is a new member.

    Medical Advisory Board

     

    • Chairman, Barry D. Pressman, MD, FAC, Professor & Chair, Department of Imaging, Mark Taper Foundation Imaging Center, Cedars-Sinai Medical Center

    • Albert Denittis, M.D., Chief of Radiation Oncology, Lankenau Medical Center 

    • Beau Toskich, M.D. received special permission from the Mayo Clinic to join our Board.

    HUMAN SECTOR

    VX-2 Animal Study

    The Phase Two 100Gy injections were completed. The focus was on treating margins of a complex tumor morphology tumor shape for future publications. Next month the 400 Gy injections will be administered. CT imaging of tumor volume is being measured over time to track effectiveness. Histopathology analysis is also ongoing. The final report is being outlined for the Phase One portion for submission to the FDA.

    FDA Pre-Submission Meeting

    We presented to the FDA the case for the urgent benefit of RadioGel™ Precision Radionuclide Therapy (PRnT) over the current standard of care, our proposed path forward to respond to their new comments on genotoxicity(1), the preliminary VX2 animal study results, and a summary data on the effectiveness of IsoPet in treating animals. The post-meeting focus is now on completing the final VX2 report and responding to the new genotoxicity comments.

     

    Our tactic is to continuously make progress toward achieving the final Investigational Device Exemption (IDE), by amending the previous draft IDE submissions. Each time we address their written comments and add our new data. Our next amendment will address the recent new written comments and feedback from the meeting. This approach allows us to harvest the progress over time.

    1). Genotoxicity refers to the capability of a substance to damage the genetic information of cells (changes of the structure, sequence, and/or number of genes) 

    Mayo Clinic Surrogate Training session

    Another surrogate session was conducted at Mayo Clinic to complete a requirement of our training plan for eventual human therapy. This was a full-dress rehearsal injecting three regions of a warmed chicken breast to simulate three different-sized lymph nodes using the Injection Guidance Table and the new improved equipment.

     

    The session went perfectly and we now are incorporating a new suggestion from the Mayo therapists to fill each dedicated syringe with the exact amount recommended in the Guidance. This improves the precision of the administered activity. Our final surrogate training session will be at the activity concentration recommended to achieve the prescribed dose for treating cancerous lymph nodes.

    ANIMAL SECTOR

    New Clinics

    This month the state of New Hampshire regulators approved the Y-90 material handling license for Myhre Clinic. The final step is to complete the low-activity surrogate training session. 

    IsoPet® Solutions

    We recently added the domain www.isopetsolutions.com to our portfolio. 

     

    This will be the new home for IsoPet® veterinary information. The focus of this website will supply Veterinarian's with pet oncology information and the on going training section for treating animals with IsoPet® Precision Radionuclide Therapy (PRnT). This will allow our RadioGel™ website to become more focused on information related to future Human Therapies. While under construction to the current website has limited information with links to RadioGel™.

     

    The complete website is planned to be launched in May 2023.

    Thank you for your continued support. 

     

    Mike Korenko, Sc. D

    CEO & President Vivos, Inc.

    CONTACT:
    Vivos Inc.
    Michael K. Korenko, Sc.D.
    President & CEO

    tagPlaceholderTags:

    Vivos, Inc.

    Precision Radionuclide Therapy (PRnT)

    OTCQB: RDGL

    contact: info@radiogel.com


    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB: RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
       text color
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
     
    has-right-nav g-font has-top-header
     
    Navigation styles
     
    size-15 weight-400 snip-nav
     
    Content styles
     
    form-white
     
    Footer styles
     
    o-form

     

    Typography

    Heading H1
    weight-400
     
    Heading H2
    weight-400
     
    Heading H3
    weight-400
     
    Buttons
    weight-400
     
    Animations
     

    Note:
    All changes made here will be applied to your entire website.
    is-switcher

    RadioGel™ Logo

    Precision Radionuclide Therapy™ (PRnT)

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top